

**Summary of National Clinical Trials Network (NCTN) Strategic Planning Working Group Meeting - July 11, 2012**

1. Goals of Working Group review of NCTN clinical trial portfolio in each disease area are:
  - a. Assess strength and balance of active trials
  - b. Provide strategic advice to NCI regarding opportunities/resource allocation within and across disease areas.
    - i. Pilot review of colorectal trials indicated that opportunities to provide such strategic advice are likely to result from review of trial portfolios.
  - c. Provide advice on improving the scientific effectiveness of individual Scientific Steering Committees and of the overall Scientific Steering Committee system.
    - i. Pilot review of colorectal trials indicated that opportunities to provide such advice are likely to result from review of trial portfolios.
2. Assessment of pilot process used for review of colorectal clinical trial portfolio
  - a. Review of individual trials within a disease portfolio is appropriate and feasible
  - b. Working Group is appropriate venue for conducting such a review
  - c. Working Group is comfortable with using expert judgment to evaluate individual trials
  - d. Summary sheets on individual trials provided in advance are valuable
  - e. Need summary information on other major ongoing trials (e.g., industry, international) in disease area
  - f. Presentation of clinical trial portfolio and strategy in disease area by CTEP Medical Officer and Steering Committee Chair valuable for putting trials in context and understanding the basis for Steering Committee decisions
3. Future meetings
  - a. Conclusion that multiple diseases could be covered per day, especially if information received sufficiently in advance that members could reach preliminary conclusions on individual trials before the meeting
  - b. Two-day meetings are preferable to single-day meetings to facilitate completing review for all disease areas.
  - c. Would be valuable to assign a subset of Working Group members to take lead in review of each disease area
4. Proposed criteria for evaluating trials
  - a. Feasibility
  - b. Clinical Importance
  - c. Scientific contribution
  - d. Relative cost/resources
  - e. Appropriateness for NCTN Program
5. Overall score for each trial
  - a. Conclusion that Working Group members should assign an overall score to each trial based on their scores on the individual criteria

- b. No decision reached as to whether the individual criteria should be weighted in a standard manner for obtaining an overall score.